First malaria vaccine meets WHO efficacy criteria
Researchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.
European COVID-19 antibody enters Phase III testing
GSK’s and Vir Therapeutics COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UKs COVID-19 drug testing platform, AGILE
J&J starts European COVID-19 vaccine roll-out
After a positive re-evaluation of J&Js COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU.
Endeavour Medtech Growth II LP closes at $375m
Endeavour Vision has announced the closing of its Heathtech fund Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.
Record year for Swiss biotech industry
The Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.
EU orders 100 million additional doses from Biontech
COVID-19: Study finds neutralising antibodies to disappear rapidly
A new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
BioVersys gets 20m EIB loan to develop novel antibiotics
Swiss BioVersys has received 20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink 414m IL-17A blocker R&D contract
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Next-gen COVID-19 vaccine good in preclinical tests
Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)